Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 6/20 | 0.43 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241160 | 1.00 | IGF1R (0.43) | IGF1RHMOX1MEN1KMT2ACYP2A6 | |
| SCHEMBL2368070 | 1.00 | IGF1R (0.43) | IGF1RHMOX1MEN1KMT2ACYP2A6 | |
| SCHEMBL30096318 | 0.90 | IGF1R (0.41) | IGF1RHMOX1MEN1KMT2ACYP2A6 | |
| SCHEMBL29761241 | 0.89 | AOC3 (0.43) | IGF1RHMOX1MEN1KMT2ACXCR3 | |
| SCHEMBL16070654 | 0.88 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ACYP2A6 | |
| SCHEMBL3175979 | 0.88 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ACYP2A6 | |
| SCHEMBL16070705 | 0.88 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ACYP2A6 | |
| SCHEMBL3839205 | 0.88 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ACYP2A6 | |
| SCHEMBL6111588 | 0.86 | KMT2A (0.41) | IGF1RHMOX1KMT2ACXCR3CYP1A2 | |
| SCHEMBL16070602 | 0.86 | IGF1R (0.39) | IGF1RHMOX1MEN1KMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2628481-B1 | Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV | ABBVIE BAHAMAS LTD (BS) | 2016-02-24 | — | — | EP | disclosed |
| US-20150218194-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-9006387-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2853531-A2 | Antiviral compounds | AbbVie Bahamas Ltd. (BS) | 2015-04-01 | — | — | EP | disclosed |
| EP-2455376-B1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | ABBVIE BAHAMAS LTD (BS) | 2014-11-26 | — | — | EP | disclosed |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES | 2014-10-23 | — | — | US | disclosed |
| EP-2337781-B1 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | ABBVIE BAHAMAS LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2368890-B9 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-10-30 | — | — | EP | disclosed |
| EP-2628481-A1 | Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV | AbbVie Bahamas Ltd. (BS) | 2013-08-21 | — | — | EP | disclosed |
| EP-2368890-B1 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-04-17 | — | — | EP | disclosed |
| EP-2455376-A1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2337781-A2 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | Abbott Laboratories (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144646-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | IGF1R 4713/4885HMOX1 419/4885MEN1 4681/4885 |
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | IGF1R 4713/4885HMOX1 419/4885MEN1 4681/4885 |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | IGF1R 4713/4885HMOX1 419/4885MEN1 4681/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | IGF1R 4713/4885HMOX1 419/4885MEN1 4681/4885 |
| US-20150218194-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | IGF1R 4713/4885HMOX1 419/4885MEN1 4681/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | IGF1R 4713/4885HMOX1 419/4885MEN1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.